newsfilter
← Latest News
GlobeNewswire·

Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland November 22, 2021 – Obseva SA (NASDAQ